Sotera Health(US:SHC)2025-08-08 13:00Q2 2025 Financial Highlights - Net revenues increased by 64% to $294341 million, or 60% on a constant currency basis, compared to Q2 2024[35, 69] - Adjusted EBITDA increased by 98% to $150735 million, or 95% on a constant currency basis, compared to Q2 2024[29, 69] - Adjusted EBITDA margin increased by 156 basis points to 512% compared to Q2 2024[29, 35] - Adjusted EPS increased by $001 to $020 compared to Q2 2024[29, 35] Segment Performance - Sterigenics revenue increased by 105% to $194839 million in Q2 2025[38, 69] - Nordion revenue increased by 29% to $42431 million in Q2 2025[42, 69] - Nelson Labs revenue decreased by 33% to $57071 million in Q2 2025[46, 69] Liquidity and Capital Deployment - Strong liquidity position of $918 million as of June 30, 2025, with no outstanding borrowings on the revolving line of credit[32, 51] - Net Leverage Ratio improved to 35x as of June 30, 2025, compared to 37x as of December 31, 2024[32, 53] Full-Year 2025 Outlook - Net Revenues are expected to increase by 45% to 60%[60] - Adjusted EBITDA is expected to increase by 60% to 75%[60] - Adjusted EPS is expected to be $075 to $082[60]